*** Exciting New Alert ECTE ***
when I said this alert is quite exciting. Things have been good
lately, we made 35% and 40% gains off the Sunday Night Specials and to
top it off…my last 6 out of 7 picks have been winners.
I hope to keep it up with this next one. This email is a little long
because I have a lot to say about this company, but I think it’s worth
reading…
who follow my newsletter regularly know that I prefer to send out picks
for companies that I can relate to on a personal level. Companies that
operate in fields that I have experience with in my own life, so I can
truly understand how people need the products or services the company
provides. It kind of gives me a better understanding on how the
company (and its share price) can really "take off".
stock, it’s 2 dollars. Some of my readers who like higher priced
companies will definitely want to take a look at this one. ECTE has
been trending upward since the beginning of December 2009. Volume has
been getting larger and ECTE is definitely being accumulated. There’s
no doubt about that. Echo isn’t just a good pick for me because of its
chart, Echo is truly a company with a great story, incredible
prospects, and…they actually *gasp* help people.
that actually helps people, all the better. Here are 4 reasons I like
ECTE as a real investment. They are ALL very powerful.
target for one of the major pharmaceutical companies. Even the CEO
admitted they could be a target, and once a little company gets taken
over by a big one, share prices go through the roof.
measure their blood glucose levels without having to prick themselves
with a needle. ECTE’s NEEDLE-FREE BLOOD GLUCOSE MONITORING SYSTEM IS PATENTED. NO ONE ELSE IN THE WORLD HAS THIS REVOLUTIONARY PRODUCT. Sorry to go "all caps" on you, but that is an absolutely amazing fact. It’s called the Prelude SkinPrep System.
he has it pretty bad. He can’t work, he gets light headed often, and
he has been hospitalized several times for it. He’s not dying or
anything, he’s okay…but on top of the life changes diabetes brings,
he has to prick himself with a needle and make himself bleed every
single day. It’s not that pricking yourself is the worst thing in the
world, but it’s annoying, painful, unpleasant, etc. Obviously if there
was a product that could monitor his blood glucose levels WITHOUT him
having to prick himself with a needle…he would, of course, use that
product.
insurance companies cover items like ECTE’s blood glucose monitor. If
insurance starts to cover it and the patients don’t have to pay for it
out of pocket, virtually EVERYONE with diabetes will own ECTE’s
product!!
drugs currently delivered by needle injection to be administered
without a needle by using its patented technology of transdermal drug
administration. This may mean "shots" as we know them, may one day become a thing of the past and ECTE will be the one profiting from it.
people with diabetes buy, and possibly even get covered by insurance,
but it may also replace the current outdated needle-prick technology in
all of America’s hospitals and doctor’s offices!
in my opinion) to ECTE are CLSN which is at $3.12 and PUMD which is at
$2.50. CLSN is on the NASDAQ, which is a good example of where ECTE’s
price could easily go when it reaches AMEX or NASDAQ. PUMD, also on
the OTC, is not even close to as good as ECTE and it’s $2.50. As I
write this ECTE is only $2 and is clearly the best of these 3
companies. This shows me that ECTE is dramatically undervalued
currently.
to have a strong likelihood that this product will soon be the standard
for diabetes patients both at home and in medical facilities. They are
a strong takeover target, and, if things go very well…their unique
technology may make needle injections obsolete.
The Trader
Disclaimer – By
reading our newsletter and our website you agree to the terms of our disclaimer,
which are subject to change at any time. We are not registered or licensed in
any jurisdiction whatsoever to provide financial
advice or anything of an advisory nature. Always do your own
research and/or consult with an investment professional before investing. Low
priced stocks are speculative and carry a high degree of risk, so only invest
what you can afford to lose. By using our service you agree not to hold our
site, its editor’s, owners, or staff liable for any damages, financial or
otherwise, that may occur due to any action you may take based on the
information contained within our newsletters or on our website. We do not
advise any reader take any specific action. Our website and newsletter is for
informational and educational purposes only. Never invest purely based on our
alerts. Gains mentioned in our newsletter and on our website may be based on
EOD or intraday data. This publication and their owners and affiliates may hold
positions in the securities mentioned in our alerts, which we may sell at any
time without notice to our subscribers, which may have a negative impact on share prices. We have been compensated up to twenty thousand dollars to profile ecte by a third party. This
compensation constitutes a conflict
of interest in our ability to be unbiased. Our emails may contain
Forward Loking Statements, which are not guaranteed to materialize due to a
variety of factors. We do not guarantee the timeliness, accuracy, or
completeness of the information on our site or in our newsletters. The
information in our email newsletters and on our website is believed to be
accurate and correct, but has not been independently verified. The information
in our disclaimers is subject to change at any time without notice. See full
disclaimer at topgunstockpicks/disclaimer
?
|
|
|
View this message in the iContact Community:  View message  Comment on this message  Receive as RSS |
|
Share this message with others:  del.icio.us  Digg    StumbleUpon |
